Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has announced its intention to re-appoint PKF Littlejohn LLP as its external auditor for the financial year ending December 2025, following a formal tender process. This decision, recommended by the Audit Committee and subject to shareholder approval, aligns with the mandatory lead audit partner rotation and reflects the company’s compliance with public interest entity requirements.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 51,123
Technical Sentiment Signal: Hold
Current Market Cap: £8.86M
For detailed information about HEMO stock, go to TipRanks’ Stock Analysis page.